Actively Recruiting
Vascular Biomarkers Predictive of the Progression From Hypertensive Disorders in Pregnancy to Preeclampsia in Pregnant Women
Led by Assistance Publique - Hôpitaux de Paris · Updated on 2025-09-12
110
Participants Needed
3
Research Sites
172 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Hypertension during pregnancy remains a leading cause of maternal and fetal morbidity and mortality. The frequency (5 to 10% of pregnancies) and potential severity of these diseases, both for the mother and the child, are reasons for standardizing and optimizing medical practices. The cause of hypertension during pregnancy is quite complex, as it depends on a number of factors. Among the hypertensive disorders in pregnancy (HDP), the pathophysiology of pre-eclampsia (one of the most studied in terms of severity) remains poorly understood. The evolution of international guidelines in recent years has made it possible to distinguish various HDP, but schematically we distinguish two main entities by the existence of proteinuria from and after the 20th week of amenorrhea and by maternal-fetal complications, more serious in pre-eclampsia than in gestational hypertension. Acute placental vasculature and blood flow abnormalities were observed during gestational hypertension and preeclampsia, and maybe due to generalized vascular endothelial activation and vasospasm resulting in systemic hypertension and organ hypoperfusion. Endothelial dysfunction (ED) and abnormal expression of several specific blood biomarkers are now well accepted as characteristics of preeclampsia as a leader. However, the progression of any HDP to preeclampsia is possible, but difficult to predict. By way of example, among between 15 and 40 % of gestational hypertension cases progress to preeclampsia, suggesting that it is the same worsening disease. ED could be pre-existing (chronic, white-coat or masked hypertension) but also at the origin of gestational hypertension (unclassified hypertension, transient pregnancy hypertension), and subsequent development of preeclampsia through an imbalance between pro- and anti-angiogenic factors. An imbalance of pro-angiogenic and anti-angiogenic proteins can testify to ED, as can adequate levels of endothelial microparticles. The main objective of this research is to assess the presence of urinary endothelial microparticles in stable pregnant women with hypertensive disorder of pregnancy as a marker for the occurrence of pre-eclampsia during pregnancy.
CONDITIONS
Official Title
Vascular Biomarkers Predictive of the Progression From Hypertensive Disorders in Pregnancy to Preeclampsia in Pregnant Women
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients with a hypertensive disorder in pregnancy and/or preeclampsia from 20 to 26 �b1 2 weeks of pregnancy
- Age between 18 and 40 years old
- Provided written informed consent
- Affiliated with a social security scheme
You will not qualify if you...
- Known complex diabetes treated before pregnancy
- Known high cholesterol (LDL > 130 mg/dl)
- Multicomplicated connective tissue disease
- Established cardiovascular disease (ischemic heart disease, stroke, lower limb artery disease, heart failure)
- Pre-existing kidney failure (serum creatinine > 125 �b5mol/L) or proteinuria �b1 300 mg/24h
- Cardiac arrhythmia
- Hepatitis C or HIV infection (tested within 6 months before preeclampsia diagnosis)
- Recent venous or arterial thrombotic event (within 3 months)
- Currently enrolled in another treatment study
- Under legal protective measures
- Receiving State Medical Assistance
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 3 locations
1
AP-HP Avicenne Hospital, Department of internal medicine
Bobigny, Seine Saint Denis, France, 93000
Actively Recruiting
2
AP-HP Jean Verdier Hospital, Gynecology and Obstetrics Department
Bondy, Seine Saint Denis, France, 93140
Actively Recruiting
3
AP-HP Laribosière Hospital, Gynecology and Obstetrics Department
Paris, France, 75010
Actively Recruiting
Research Team
M
Marilucy LOPEZ-SUBLET, MD
CONTACT
L
Lionel CARBILLON, MD PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
PREVENTION
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here